Mirum Pharmaceuticals, Inc. (MIRM) – What Are Investment Firms Thinking About This Stock?

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been assigned a consensus rating of “Moderate Buy” from the fifteen brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $155.56.

Several brokerages recently issued reports on MIRM. Morgan Stanley upped their price target on shares of Mirum Pharmaceuticals from $137.00 to $152.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Raymond James Financial reissued a “strong-buy” rating and set a $189.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 4th. HC Wainwright raised their price objective on shares of Mirum Pharmaceuticals from $200.00 to $202.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Leerink Partners dropped their target price on shares of Mirum Pharmaceuticals from $154.00 to $140.00 and set an “outperform” rating for the company in a research note on Thursday, November 5th. Finally, UBS Group set a $137.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th.

Insiders Place Their Bets

In other news, SVP Jolanda Howe sold 40,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total value of $4,000,000.00. Following the transaction, the senior vice president owned 1,274 shares of the company’s stock, valued at approximately $127,400. This trade represents a 96.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Laura Brege sold 14,167 shares of the firm’s stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $94.21, for a total transaction of $1,334,673.07. Following the completion of the transaction, the director directly owned 15,703 shares in the company, valued at approximately $1,479,379.63. The trade was a 47.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 104,825 shares of company stock valued at $10,160,873. 8.32% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Contravisory Investment Management Inc. lifted its position in shares of Mirum Pharmaceuticals by 2.3% during the second quarter. Contravisory Investment Management Inc. now owns 4,604 shares of the company’s stock worth $539,000 after purchasing an additional 103 shares during the last quarter. Knights of Columbus Asset Advisors LLC grew its stake in Mirum Pharmaceuticals by 0.5% in the third quarter. Knights of Columbus Asset Advisors LLC now owns 23,944 shares of the company’s stock worth $2,047,000 after purchasing an additional 113 shares in the last quarter. ABS Investment Management LLC acquired a new position in Mirum Pharmaceuticals in the second quarter worth about $245,847,000. Integrated Wealth Concepts LLC bought a new stake in Mirum Pharmaceuticals in the second quarter valued at about $27,000. Finally, Commonwealth Equity Services LLC increased its holdings in Mirum Pharmaceuticals by 10.8% in the third quarter. Commonwealth Equity Services LLC now owns 2,471 shares of the company’s stock valued at $211,000 after buying an additional 241 shares during the last quarter.

Mirum Pharmaceuticals Price Performance

NASDAQ:MIRM traded up $0.66 during mid-day trading on Friday, hitting $93.99. The company’s stock had a trading volume of 331,049 shares, compared to its average volume of 616,358. The company has a market capitalization of $6.14 billion, a price-to-earnings ratio of -6.08 and a beta of 0.75. The company has a current ratio of 2.07, a quick ratio of 1.98 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals has a fifty-two week low of $63.23 and a fifty-two week high of $130.00. The stock has a fifty day moving average of $88.79 and a 200-day moving average of $98.41.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.38). Mirum Pharmaceuticals had a negative return on equity of 97.25% and a negative net margin of 134.75%. The company had revenue of $185.72 million for the quarter, compared to analyst estimates of $178.07 million. During the same quarter in the prior year, the company earned $0.05 earnings per share. The business’s revenue was up 39.6% compared to the same quarter last year. As a group, equities analysts forecast that Mirum Pharmaceuticals will post -1.47 EPS for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.